1. Home
  2. PG vs AZN Comparison

PG vs AZN Comparison

Compare PG & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Procter & Gamble Company (The)

PG

Procter & Gamble Company (The)

HOLD

Current Price

$145.90

Market Cap

369.9B

ML Signal

HOLD

Logo AstraZeneca PLC

AZN

AstraZeneca PLC

HOLD

Current Price

$192.12

Market Cap

316.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PG
AZN
Founded
1837
1992
Country
United States
United Kingdom
Employees
N/A
96100
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
369.9B
316.4B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
PG
AZN
Price
$145.90
$192.12
Analyst Decision
Buy
Strong Buy
Analyst Count
18
1
Target Price
$167.28
N/A
AVG Volume (30 Days)
6.5M
1.8M
Earning Date
04-24-2026
04-29-2026
Dividend Yield
2.96%
1.64%
EPS Growth
8.14
N/A
EPS
3.73
N/A
Revenue
$84,284,000,000.00
N/A
Revenue This Year
$5.76
$10.34
Revenue Next Year
$2.57
$6.43
P/E Ratio
$38.30
$31.91
Revenue Growth
0.29
N/A
52 Week Low
$137.62
$66.16
52 Week High
$170.99
$212.71

Technical Indicators

Market Signals
Indicator
PG
AZN
Relative Strength Index (RSI) 50.41 44.00
Support Level $144.09 $182.39
Resistance Level $147.70 $208.61
Average True Range (ATR) 2.50 3.22
MACD 0.49 -1.60
Stochastic Oscillator 76.50 1.44

Price Performance

Historical Comparison
PG
AZN

About PG Procter & Gamble Company (The)

Since its founding in 1837, Procter & Gamble has become one of the world's largest consumer product manufacturers, with annual sales of nearly $85 billion. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent just more than half of the firm's consolidated total.

About AZN AstraZeneca PLC

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Share on Social Networks: